 Paul Norman
Concepts (476)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, KIR | 58 | 2025 | 96 | 10.310 |
Why?
| | Killer Cells, Natural | 54 | 2025 | 426 | 7.260 |
Why?
| | Haplotypes | 42 | 2025 | 474 | 4.350 |
Why?
| | Alleles | 47 | 2025 | 843 | 3.850 |
Why?
| | Genes, MHC Class I | 12 | 2022 | 34 | 3.610 |
Why?
| | Histocompatibility Antigens Class I | 17 | 2024 | 200 | 3.540 |
Why?
| | HLA Antigens | 21 | 2024 | 235 | 3.210 |
Why?
| | HLA-B Antigens | 21 | 2025 | 62 | 3.100 |
Why?
| | HLA-C Antigens | 19 | 2024 | 35 | 3.080 |
Why?
| | Polymorphism, Genetic | 30 | 2024 | 636 | 2.580 |
Why?
| | Receptors, KIR3DL1 | 13 | 2024 | 17 | 2.310 |
Why?
| | Immunogenetics | 5 | 2024 | 7 | 2.130 |
Why?
| | Receptors, KIR2DL1 | 12 | 2024 | 18 | 2.110 |
Why?
| | Genotype | 33 | 2025 | 1827 | 2.100 |
Why?
| | Evolution, Molecular | 18 | 2022 | 460 | 1.810 |
Why?
| | High-Throughput Nucleotide Sequencing | 15 | 2025 | 486 | 1.400 |
Why?
| | Selection, Genetic | 12 | 2024 | 252 | 1.380 |
Why?
| | HLA-A Antigens | 11 | 2023 | 53 | 1.320 |
Why?
| | Receptors, KIR3DS1 | 4 | 2022 | 6 | 1.270 |
Why?
| | Genetic Variation | 18 | 2024 | 936 | 1.240 |
Why?
| | Receptors, Immunologic | 9 | 2021 | 216 | 1.140 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2025 | 50 | 1.050 |
Why?
| | Genes, MHC Class II | 2 | 2017 | 73 | 1.010 |
Why?
| | Gene Frequency | 18 | 2024 | 500 | 0.940 |
Why?
| | Sequence Deletion | 1 | 2025 | 178 | 0.900 |
Why?
| | Immunogenetic Phenomena | 2 | 2022 | 7 | 0.870 |
Why?
| | Medication Errors | 1 | 2024 | 96 | 0.870 |
Why?
| | Pre-Eclampsia | 3 | 2020 | 187 | 0.810 |
Why?
| | Multimorbidity | 1 | 2023 | 46 | 0.810 |
Why?
| | Ligands | 15 | 2023 | 619 | 0.810 |
Why?
| | Humans | 128 | 2025 | 129527 | 0.810 |
Why?
| | Herpesviridae | 1 | 2022 | 22 | 0.770 |
Why?
| | Receptors, Natural Killer Cell | 6 | 2022 | 16 | 0.770 |
Why?
| | Focus Groups | 1 | 2024 | 447 | 0.770 |
Why?
| | Genome-Wide Association Study | 4 | 2024 | 1326 | 0.770 |
Why?
| | Primates | 3 | 2019 | 120 | 0.740 |
Why?
| | Qualitative Research | 3 | 2024 | 1231 | 0.740 |
Why?
| | Herpesviridae Infections | 1 | 2023 | 142 | 0.740 |
Why?
| | Patient Safety | 1 | 2024 | 287 | 0.730 |
Why?
| | Communicable Diseases | 1 | 2023 | 152 | 0.710 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2023 | 855 | 0.690 |
Why?
| | Genome, Human | 5 | 2017 | 393 | 0.670 |
Why?
| | Genetics, Population | 10 | 2021 | 200 | 0.650 |
Why?
| | Intensive Care Units | 1 | 2024 | 737 | 0.640 |
Why?
| | Peptides | 4 | 2022 | 925 | 0.620 |
Why?
| | Hematopoietic Stem Cell Transplantation | 6 | 2024 | 577 | 0.620 |
Why?
| | Major Histocompatibility Complex | 3 | 2024 | 229 | 0.610 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2023 | 363 | 0.610 |
Why?
| | Point Mutation | 3 | 2017 | 224 | 0.590 |
Why?
| | Receptors, KIR2DL4 | 3 | 2016 | 4 | 0.580 |
Why?
| | Heterozygote | 1 | 2019 | 270 | 0.570 |
Why?
| | Pan troglodytes | 9 | 2017 | 58 | 0.570 |
Why?
| | Complement C4 | 1 | 2017 | 25 | 0.540 |
Why?
| | Genotyping Techniques | 4 | 2025 | 72 | 0.540 |
Why?
| | Leukemia | 1 | 2019 | 230 | 0.540 |
Why?
| | Protein Binding | 10 | 2019 | 2121 | 0.530 |
Why?
| | Mucins | 1 | 2017 | 70 | 0.520 |
Why?
| | Linkage Disequilibrium | 10 | 2017 | 257 | 0.510 |
Why?
| | Immunoglobulin Fc Fragments | 2 | 2015 | 39 | 0.490 |
Why?
| | Immunoglobulins | 4 | 2023 | 162 | 0.480 |
Why?
| | Polymorphism, Single Nucleotide | 12 | 2025 | 2062 | 0.460 |
Why?
| | Genetic Predisposition to Disease | 8 | 2024 | 2271 | 0.460 |
Why?
| | Exons | 1 | 2016 | 340 | 0.460 |
Why?
| | Population | 1 | 2014 | 34 | 0.450 |
Why?
| | Immunity, Innate | 7 | 2024 | 804 | 0.430 |
Why?
| | Receptors, KIR2DL2 | 5 | 2021 | 6 | 0.430 |
Why?
| | Sequence Analysis, DNA | 8 | 2025 | 776 | 0.430 |
Why?
| | Receptors, KIR2DL3 | 6 | 2017 | 9 | 0.420 |
Why?
| | DNA Copy Number Variations | 4 | 2025 | 167 | 0.420 |
Why?
| | Malaria | 1 | 2013 | 59 | 0.410 |
Why?
| | Cell Line | 8 | 2019 | 2774 | 0.410 |
Why?
| | Histocompatibility Testing | 4 | 2024 | 121 | 0.400 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1311 | 0.380 |
Why?
| | Cytomegalovirus | 3 | 2024 | 154 | 0.360 |
Why?
| | T-Lymphocytes | 6 | 2024 | 1935 | 0.360 |
Why?
| | Molecular Sequence Data | 14 | 2014 | 2827 | 0.360 |
Why?
| | United Kingdom | 4 | 2024 | 257 | 0.350 |
Why?
| | Biological Evolution | 5 | 2019 | 435 | 0.340 |
Why?
| | Behcet Syndrome | 2 | 2021 | 18 | 0.340 |
Why?
| | Burns | 2 | 2024 | 292 | 0.340 |
Why?
| | Epitopes | 8 | 2019 | 473 | 0.330 |
Why?
| | Minority Groups | 2 | 2024 | 250 | 0.320 |
Why?
| | Amino Acid Sequence | 9 | 2019 | 2055 | 0.320 |
Why?
| | Meiosis | 1 | 2009 | 65 | 0.310 |
Why?
| | Antigens, CD | 5 | 2017 | 485 | 0.310 |
Why?
| | Recombination, Genetic | 2 | 2010 | 187 | 0.310 |
Why?
| | Models, Molecular | 5 | 2019 | 1487 | 0.310 |
Why?
| | Cytomegalovirus Infections | 2 | 2024 | 190 | 0.310 |
Why?
| | Phylogeny | 12 | 2017 | 843 | 0.290 |
Why?
| | China | 3 | 2024 | 192 | 0.280 |
Why?
| | Object Attachment | 2 | 2019 | 41 | 0.280 |
Why?
| | Female | 36 | 2025 | 68650 | 0.280 |
Why?
| | Oceania | 2 | 2024 | 4 | 0.270 |
Why?
| | Male | 30 | 2025 | 63586 | 0.270 |
Why?
| | Homozygote | 2 | 2025 | 195 | 0.270 |
Why?
| | Immune System | 2 | 2019 | 174 | 0.260 |
Why?
| | Body Image | 2 | 2024 | 84 | 0.260 |
Why?
| | Signal Transduction | 3 | 2019 | 4916 | 0.260 |
Why?
| | Multigene Family | 3 | 2018 | 195 | 0.260 |
Why?
| | Egypt | 2 | 2023 | 10 | 0.260 |
Why?
| | HLA-A24 Antigen | 2 | 2024 | 6 | 0.250 |
Why?
| | Software | 4 | 2025 | 608 | 0.250 |
Why?
| | Virus Activation | 2 | 2024 | 88 | 0.250 |
Why?
| | Amino Acid Substitution | 5 | 2016 | 284 | 0.250 |
Why?
| | Codon | 2 | 2016 | 84 | 0.250 |
Why?
| | Quality of Life | 4 | 2023 | 2694 | 0.250 |
Why?
| | Genomics | 5 | 2021 | 715 | 0.240 |
Why?
| | Thymus Gland | 2 | 2024 | 309 | 0.240 |
Why?
| | Phenotype | 7 | 2024 | 3058 | 0.230 |
Why?
| | Self Concept | 2 | 2024 | 240 | 0.230 |
Why?
| | Animals | 26 | 2024 | 35334 | 0.230 |
Why?
| | Hominidae | 2 | 2019 | 81 | 0.230 |
Why?
| | Seizures | 2 | 2019 | 402 | 0.230 |
Why?
| | Interpersonal Relations | 2 | 2019 | 394 | 0.220 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2024 | 17 | 0.220 |
Why?
| | Myocardial Infarction | 2 | 2023 | 1018 | 0.220 |
Why?
| | Iodine Radioisotopes | 1 | 2024 | 140 | 0.220 |
Why?
| | Parkinson Disease | 2 | 2020 | 462 | 0.220 |
Why?
| | Phenylurea Compounds | 1 | 2024 | 88 | 0.220 |
Why?
| | Australia | 1 | 2024 | 242 | 0.220 |
Why?
| | Pedigree | 1 | 2025 | 482 | 0.210 |
Why?
| | Arabs | 2 | 2020 | 5 | 0.210 |
Why?
| | Quinolines | 1 | 2024 | 156 | 0.210 |
Why?
| | HLA-DP beta-Chains | 1 | 2023 | 84 | 0.210 |
Why?
| | Immunity, Cellular | 1 | 2005 | 265 | 0.210 |
Why?
| | Computational Biology | 2 | 2025 | 591 | 0.200 |
Why?
| | Gene Dosage | 3 | 2021 | 141 | 0.200 |
Why?
| | Iran | 2 | 2020 | 38 | 0.200 |
Why?
| | Centromere | 2 | 2015 | 48 | 0.200 |
Why?
| | Transplantation Conditioning | 1 | 2024 | 166 | 0.200 |
Why?
| | Leukocytes | 1 | 2004 | 304 | 0.200 |
Why?
| | Lymphocyte Activation | 5 | 2021 | 1109 | 0.200 |
Why?
| | Sequence Alignment | 3 | 2021 | 330 | 0.200 |
Why?
| | Patient Transfer | 1 | 2024 | 163 | 0.200 |
Why?
| | Africa, Southern | 2 | 2021 | 8 | 0.190 |
Why?
| | Empathy | 1 | 2024 | 169 | 0.190 |
Why?
| | Toll-Like Receptor 3 | 1 | 2021 | 27 | 0.190 |
Why?
| | Adult | 20 | 2024 | 35505 | 0.190 |
Why?
| | Longevity | 1 | 2023 | 155 | 0.190 |
Why?
| | Health | 1 | 2022 | 75 | 0.190 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 336 | 0.180 |
Why?
| | Genomic Structural Variation | 1 | 2021 | 12 | 0.180 |
Why?
| | Yersinia pestis | 1 | 2021 | 44 | 0.180 |
Why?
| | Nutritionists | 1 | 2021 | 16 | 0.180 |
Why?
| | Malaysia | 1 | 2020 | 4 | 0.180 |
Why?
| | Protein Interaction Domains and Motifs | 2 | 2019 | 139 | 0.180 |
Why?
| | HLA-DRB1 Chains | 3 | 2019 | 108 | 0.180 |
Why?
| | HLA-D Antigens | 1 | 2021 | 34 | 0.180 |
Why?
| | Plague | 1 | 2021 | 58 | 0.170 |
Why?
| | Thyroid Neoplasms | 1 | 2024 | 305 | 0.170 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2021 | 68 | 0.170 |
Why?
| | Psoriasis | 1 | 2021 | 87 | 0.170 |
Why?
| | Pregnancy | 6 | 2020 | 6412 | 0.170 |
Why?
| | Malnutrition | 1 | 2021 | 79 | 0.170 |
Why?
| | Natural Cytotoxicity Triggering Receptor 2 | 1 | 2019 | 2 | 0.160 |
Why?
| | Transportation | 1 | 2019 | 50 | 0.160 |
Why?
| | Clathrin Heavy Chains | 1 | 2019 | 3 | 0.160 |
Why?
| | Protozoan Infections | 1 | 2019 | 10 | 0.160 |
Why?
| | HLA-DP Antigens | 1 | 2019 | 32 | 0.160 |
Why?
| | B-Lymphocytes | 4 | 2017 | 816 | 0.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 755 | 0.160 |
Why?
| | Base Sequence | 3 | 2016 | 2138 | 0.150 |
Why?
| | Telomere | 3 | 2014 | 232 | 0.150 |
Why?
| | Bicycling | 1 | 2019 | 115 | 0.150 |
Why?
| | Indians, North American | 2 | 2015 | 600 | 0.150 |
Why?
| | Middle Aged | 17 | 2024 | 31087 | 0.150 |
Why?
| | Phylogeography | 1 | 2019 | 48 | 0.150 |
Why?
| | Receptors, Cell Surface | 1 | 2001 | 381 | 0.150 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2024 | 596 | 0.150 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2018 | 51 | 0.150 |
Why?
| | Africa South of the Sahara | 2 | 2019 | 42 | 0.150 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2024 | 707 | 0.150 |
Why?
| | Indians, South American | 2 | 2009 | 24 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 761 | 0.140 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2017 | 10 | 0.140 |
Why?
| | Syk Kinase | 1 | 2017 | 21 | 0.140 |
Why?
| | Employment | 1 | 2019 | 167 | 0.140 |
Why?
| | Multifactorial Inheritance | 1 | 2019 | 150 | 0.140 |
Why?
| | Flow Cytometry | 7 | 2018 | 1158 | 0.140 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 548 | 0.140 |
Why?
| | Binding Sites | 6 | 2015 | 1250 | 0.140 |
Why?
| | Epilepsy | 2 | 2019 | 322 | 0.140 |
Why?
| | Lymphocyte Subsets | 3 | 2009 | 84 | 0.140 |
Why?
| | Pan paniscus | 1 | 2017 | 4 | 0.140 |
Why?
| | Contig Mapping | 1 | 2017 | 10 | 0.140 |
Why?
| | Immunodominant Epitopes | 1 | 2017 | 28 | 0.140 |
Why?
| | Pongo | 1 | 2017 | 6 | 0.140 |
Why?
| | Transplantation, Homologous | 4 | 2024 | 402 | 0.140 |
Why?
| | Protein Structure, Tertiary | 5 | 2015 | 842 | 0.140 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2544 | 0.140 |
Why?
| | Incidence | 2 | 2020 | 2643 | 0.130 |
Why?
| | Models, Genetic | 4 | 2015 | 592 | 0.130 |
Why?
| | Somatoform Disorders | 1 | 2016 | 41 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 100 | 0.130 |
Why?
| | Virus Diseases | 1 | 2019 | 210 | 0.130 |
Why?
| | Open Reading Frames | 1 | 2017 | 114 | 0.130 |
Why?
| | Gene Flow | 2 | 2015 | 77 | 0.130 |
Why?
| | Reference Standards | 1 | 2017 | 176 | 0.130 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5078 | 0.130 |
Why?
| | Polymerase Chain Reaction | 5 | 2017 | 1031 | 0.130 |
Why?
| | Quality Improvement | 1 | 2024 | 1103 | 0.130 |
Why?
| | Women's Health | 1 | 2019 | 364 | 0.130 |
Why?
| | HIV-1 | 1 | 2022 | 839 | 0.130 |
Why?
| | Molecular Typing | 1 | 2016 | 21 | 0.130 |
Why?
| | Herpesvirus 4, Human | 1 | 2017 | 157 | 0.130 |
Why?
| | Placentation | 2 | 2016 | 43 | 0.130 |
Why?
| | Crohn Disease | 1 | 2019 | 217 | 0.130 |
Why?
| | Protein Conformation | 1 | 2019 | 861 | 0.120 |
Why?
| | Attitude to Health | 1 | 2019 | 432 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1559 | 0.120 |
Why?
| | Case-Control Studies | 6 | 2024 | 3383 | 0.120 |
Why?
| | Gene Expression | 4 | 2018 | 1461 | 0.120 |
Why?
| | Donor Selection | 1 | 2016 | 75 | 0.120 |
Why?
| | Sf9 Cells | 1 | 2015 | 9 | 0.120 |
Why?
| | Spodoptera | 1 | 2015 | 37 | 0.120 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2015 | 36 | 0.120 |
Why?
| | Baculoviridae | 1 | 2015 | 44 | 0.120 |
Why?
| | Human Migration | 1 | 2015 | 21 | 0.120 |
Why?
| | Walking | 1 | 2019 | 491 | 0.120 |
Why?
| | Insecta | 1 | 2015 | 63 | 0.120 |
Why?
| | Research Report | 1 | 2015 | 79 | 0.120 |
Why?
| | Smoking | 2 | 2019 | 1501 | 0.120 |
Why?
| | Physical Appearance, Body | 2 | 2024 | 2 | 0.120 |
Why?
| | Amino Acid Motifs | 5 | 2019 | 215 | 0.120 |
Why?
| | Polynesia | 1 | 2014 | 3 | 0.120 |
Why?
| | Biological Assay | 1 | 2015 | 119 | 0.110 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2015 | 86 | 0.110 |
Why?
| | Receptors, KIR3DL2 | 2 | 2015 | 2 | 0.110 |
Why?
| | New Zealand | 1 | 2014 | 45 | 0.110 |
Why?
| | Isoantibodies | 1 | 1995 | 57 | 0.110 |
Why?
| | DNA | 3 | 2021 | 1400 | 0.110 |
Why?
| | Kidney Transplantation | 2 | 2003 | 669 | 0.110 |
Why?
| | Glucose | 1 | 2019 | 996 | 0.110 |
Why?
| | Tissue Donors | 4 | 2024 | 391 | 0.110 |
Why?
| | Protein Folding | 1 | 2015 | 265 | 0.110 |
Why?
| | Mammals | 1 | 2015 | 274 | 0.110 |
Why?
| | Chromosomes, Human, Pair 19 | 2 | 2004 | 22 | 0.110 |
Why?
| | Young Adult | 7 | 2024 | 12438 | 0.100 |
Why?
| | Cell Differentiation | 4 | 2024 | 1895 | 0.100 |
Why?
| | Conserved Sequence | 2 | 2011 | 227 | 0.100 |
Why?
| | Species Specificity | 4 | 2017 | 568 | 0.100 |
Why?
| | Hematopoietic Stem Cells | 1 | 2016 | 382 | 0.100 |
Why?
| | Exome | 1 | 2014 | 216 | 0.100 |
Why?
| | Seals, Earless | 1 | 2012 | 3 | 0.100 |
Why?
| | Genetics, Medical | 3 | 2019 | 24 | 0.100 |
Why?
| | Metagenomics | 1 | 2014 | 156 | 0.100 |
Why?
| | Hepatitis C | 1 | 2015 | 244 | 0.100 |
Why?
| | Saliva | 1 | 2014 | 212 | 0.100 |
Why?
| | Anxiety | 1 | 2019 | 976 | 0.100 |
Why?
| | Graft Survival | 1 | 1995 | 514 | 0.100 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 1050 | 0.090 |
Why?
| | CD56 Antigen | 2 | 2009 | 36 | 0.090 |
Why?
| | Caregivers | 1 | 2019 | 807 | 0.090 |
Why?
| | Environment | 1 | 2013 | 345 | 0.090 |
Why?
| | Genes, Overlapping | 1 | 2011 | 2 | 0.090 |
Why?
| | Graft Rejection | 1 | 1995 | 598 | 0.090 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily C | 3 | 2017 | 8 | 0.090 |
Why?
| | Interferon-gamma | 2 | 2017 | 773 | 0.090 |
Why?
| | Hybridization, Genetic | 1 | 2011 | 73 | 0.090 |
Why?
| | DNA Primers | 3 | 2018 | 507 | 0.090 |
Why?
| | Immunoglobulin G | 1 | 1995 | 851 | 0.090 |
Why?
| | Europe | 2 | 2021 | 362 | 0.090 |
Why?
| | Depression | 1 | 2019 | 1321 | 0.080 |
Why?
| | North America | 2 | 2021 | 294 | 0.080 |
Why?
| | Mass Spectrometry | 1 | 2013 | 717 | 0.080 |
Why?
| | Gene Conversion | 1 | 2009 | 6 | 0.080 |
Why?
| | Organ Transplantation | 1 | 2013 | 228 | 0.080 |
Why?
| | Gene Products, nef | 1 | 2009 | 12 | 0.080 |
Why?
| | Receptors, IgG | 2 | 2014 | 73 | 0.080 |
Why?
| | Antigens, Bacterial | 1 | 2009 | 119 | 0.080 |
Why?
| | Stress, Psychological | 1 | 2016 | 1067 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2009 | 107 | 0.070 |
Why?
| | Africa | 3 | 2019 | 99 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 4 | 2009 | 363 | 0.070 |
Why?
| | HIV Infections | 1 | 2022 | 2729 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2342 | 0.070 |
Why?
| | Exotoxins | 1 | 2007 | 15 | 0.070 |
Why?
| | Adaptation, Psychological | 2 | 2024 | 618 | 0.070 |
Why?
| | Child | 2 | 2019 | 20932 | 0.070 |
Why?
| | Receptors, Fc | 1 | 2007 | 52 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2007 | 371 | 0.070 |
Why?
| | Immunoglobulin A | 1 | 2007 | 201 | 0.060 |
Why?
| | Aged | 7 | 2024 | 22063 | 0.060 |
Why?
| | Trinidad and Tobago | 2 | 2002 | 2 | 0.060 |
Why?
| | HLA-DR Antigens | 2 | 2006 | 223 | 0.060 |
Why?
| | Genetic Loci | 2 | 2019 | 274 | 0.060 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2734 | 0.060 |
Why?
| | Cohort Studies | 3 | 2021 | 5423 | 0.060 |
Why?
| | INDEL Mutation | 1 | 2025 | 15 | 0.060 |
Why?
| | Jurkat Cells | 2 | 2019 | 134 | 0.060 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 3181 | 0.060 |
Why?
| | Algorithms | 2 | 2024 | 1614 | 0.060 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 128 | 0.060 |
Why?
| | Histocompatibility | 1 | 2003 | 26 | 0.050 |
Why?
| | HeLa Cells | 2 | 2015 | 611 | 0.050 |
Why?
| | Lymphocyte Depletion | 1 | 2024 | 134 | 0.050 |
Why?
| | Leukocyte Immunoglobulin-like Receptor B1 | 1 | 2003 | 2 | 0.050 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2003 | 26 | 0.050 |
Why?
| | Microsatellite Repeats | 1 | 2004 | 163 | 0.050 |
Why?
| | Granzymes | 1 | 2023 | 47 | 0.050 |
Why?
| | Cell Communication | 1 | 2005 | 298 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2007 | 436 | 0.050 |
Why?
| | Lymphocytes | 1 | 2005 | 377 | 0.050 |
Why?
| | Human Immunodeficiency Virus Proteins | 1 | 2022 | 6 | 0.050 |
Why?
| | Gene Library | 2 | 2014 | 114 | 0.050 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2022 | 27 | 0.050 |
Why?
| | Africa, Western | 1 | 2002 | 17 | 0.050 |
Why?
| | Bangladesh | 1 | 2002 | 42 | 0.050 |
Why?
| | Chromosomes, Human | 1 | 2002 | 41 | 0.050 |
Why?
| | Pakistan | 1 | 2002 | 75 | 0.050 |
Why?
| | HLA-DQ Antigens | 1 | 2002 | 179 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 274 | 0.050 |
Why?
| | Cloning, Molecular | 2 | 2014 | 524 | 0.050 |
Why?
| | India | 1 | 2002 | 171 | 0.050 |
Why?
| | Software Design | 1 | 2021 | 23 | 0.050 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 55 | 0.050 |
Why?
| | Databases, Nucleic Acid | 1 | 2021 | 33 | 0.050 |
Why?
| | Quantitative Trait, Heritable | 1 | 2002 | 121 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2007 | 837 | 0.040 |
Why?
| | Thailand | 1 | 2001 | 15 | 0.040 |
Why?
| | Nutrition Assessment | 1 | 2021 | 86 | 0.040 |
Why?
| | Twins | 1 | 2001 | 247 | 0.040 |
Why?
| | England | 1 | 2019 | 74 | 0.040 |
Why?
| | Genetic Markers | 1 | 2001 | 334 | 0.040 |
Why?
| | Patient Acuity | 1 | 2019 | 45 | 0.040 |
Why?
| | Autophagy | 1 | 2021 | 265 | 0.040 |
Why?
| | Prospective Studies | 2 | 2023 | 7150 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 695 | 0.040 |
Why?
| | Celiac Disease | 1 | 2002 | 286 | 0.040 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2009 | 41 | 0.040 |
Why?
| | Mutation | 3 | 2020 | 3702 | 0.040 |
Why?
| | Nucleic Acid Denaturation | 1 | 2018 | 32 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2017 | 4087 | 0.040 |
Why?
| | Hepatitis B | 1 | 2019 | 66 | 0.040 |
Why?
| | Limit of Detection | 1 | 2018 | 83 | 0.040 |
Why?
| | Nutritional Status | 1 | 2021 | 328 | 0.040 |
Why?
| | Chromosome Mapping | 2 | 2014 | 499 | 0.040 |
Why?
| | Sex Factors | 2 | 2019 | 1966 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 885 | 0.040 |
Why?
| | Body Height | 1 | 2019 | 194 | 0.040 |
Why?
| | Mice | 3 | 2024 | 16973 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2000 | 412 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 1011 | 0.040 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1098 | 0.040 |
Why?
| | Time Factors | 4 | 2006 | 6530 | 0.030 |
Why?
| | Health Equity | 1 | 2019 | 87 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 157 | 0.030 |
Why?
| | Butyrophilins | 1 | 2017 | 6 | 0.030 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2017 | 6 | 0.030 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2017 | 17 | 0.030 |
Why?
| | Lymphocyte Count | 3 | 2002 | 148 | 0.030 |
Why?
| | Graft vs Host Disease | 1 | 2019 | 240 | 0.030 |
Why?
| | Gorilla gorilla | 1 | 2017 | 22 | 0.030 |
Why?
| | Risk Factors | 3 | 2019 | 9779 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 605 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2018 | 392 | 0.030 |
Why?
| | Computer Simulation | 1 | 2021 | 937 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2017 | 140 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2018 | 1366 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1836 | 0.030 |
Why?
| | Adolescent | 4 | 2024 | 20409 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2019 | 256 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 378 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2023 | 2724 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 1983 | 0.030 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2017 | 95 | 0.030 |
Why?
| | CD57 Antigens | 1 | 2015 | 16 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1468 | 0.030 |
Why?
| | Siberia | 1 | 2015 | 9 | 0.030 |
Why?
| | Americas | 1 | 2015 | 24 | 0.030 |
Why?
| | K562 Cells | 1 | 2015 | 85 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2016 | 161 | 0.030 |
Why?
| | Leukemia, Myeloid | 1 | 2015 | 45 | 0.030 |
Why?
| | History, Ancient | 1 | 2015 | 52 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2008 | 220 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2024 | 7052 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2001 | 1058 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 631 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 383 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2016 | 227 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2016 | 203 | 0.030 |
Why?
| | South Africa | 1 | 2015 | 193 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2019 | 326 | 0.030 |
Why?
| | Chromosomes, Mammalian | 1 | 2014 | 25 | 0.030 |
Why?
| | Genetic Fitness | 1 | 2015 | 56 | 0.030 |
Why?
| | United States | 2 | 2023 | 13865 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 277 | 0.030 |
Why?
| | Caribbean Region | 1 | 2013 | 25 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 272 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2024 | 5468 | 0.030 |
Why?
| | Mouth | 1 | 2014 | 84 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2015 | 163 | 0.030 |
Why?
| | Hospitalization | 1 | 2023 | 2076 | 0.030 |
Why?
| | Hepacivirus | 1 | 2015 | 242 | 0.030 |
Why?
| | Registries | 1 | 2021 | 1902 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2015 | 261 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2015 | 357 | 0.030 |
Why?
| | Reproduction | 1 | 2015 | 198 | 0.030 |
Why?
| | Asia | 2 | 2003 | 58 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1500 | 0.030 |
Why?
| | Demography | 1 | 2013 | 279 | 0.030 |
Why?
| | Ursidae | 1 | 2012 | 6 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 2561 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 975 | 0.020 |
Why?
| | Cell Membrane | 1 | 2016 | 733 | 0.020 |
Why?
| | Genome | 1 | 2014 | 278 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 1975 | 295 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2013 | 190 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 355 | 0.020 |
Why?
| | Feces | 1 | 2015 | 442 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2013 | 483 | 0.020 |
Why?
| | Cattle | 1 | 2014 | 959 | 0.020 |
Why?
| | Quantitative Trait Loci | 1 | 2014 | 352 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 36 | 0.020 |
Why?
| | Diet | 1 | 2019 | 1211 | 0.020 |
Why?
| | Family Practice | 1 | 1975 | 456 | 0.020 |
Why?
| | Dogs | 1 | 2012 | 385 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 988 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2013 | 349 | 0.020 |
Why?
| | Adaptation, Biological | 1 | 2011 | 55 | 0.020 |
Why?
| | HLA-A2 Antigen | 1 | 2011 | 48 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2011 | 4073 | 0.020 |
Why?
| | Uterus | 1 | 2011 | 207 | 0.020 |
Why?
| | Twins, Dizygotic | 2 | 2001 | 181 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 3968 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3255 | 0.020 |
Why?
| | Twins, Monozygotic | 2 | 2001 | 209 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1842 | 0.020 |
Why?
| | Culture | 1 | 2011 | 124 | 0.020 |
Why?
| | HLA-A11 Antigen | 1 | 2009 | 1 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2367 | 0.020 |
Why?
| | Antibody Affinity | 1 | 2009 | 59 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 10232 | 0.020 |
Why?
| | Receptors, KIR2DL5 | 1 | 2009 | 1 | 0.020 |
Why?
| | Leucine | 1 | 2009 | 109 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1717 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 371 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2009 | 342 | 0.020 |
Why?
| | Exercise | 1 | 2019 | 1931 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 262 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2009 | 438 | 0.020 |
Why?
| | Tryptophan | 1 | 2009 | 177 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2628 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2011 | 695 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2011 | 819 | 0.020 |
Why?
| | Lysine | 1 | 2009 | 286 | 0.020 |
Why?
| | Venezuela | 1 | 2006 | 7 | 0.020 |
Why?
| | Microbiota | 1 | 2014 | 734 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2007 | 141 | 0.020 |
Why?
| | Rabbits | 1 | 2007 | 769 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 1995 | 4891 | 0.020 |
Why?
| | Placenta | 1 | 2011 | 716 | 0.010 |
Why?
| | CD4-CD8 Ratio | 1 | 2005 | 22 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2005 | 75 | 0.010 |
Why?
| | Leukocyte Common Antigens | 1 | 2005 | 82 | 0.010 |
Why?
| | Microspheres | 1 | 2005 | 131 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 5429 | 0.010 |
Why?
| | Cell Separation | 1 | 2005 | 315 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2005 | 310 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1211 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2003 | 49 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2009 | 1118 | 0.010 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2002 | 16 | 0.010 |
Why?
| | HLA-DQ beta-Chains | 1 | 2002 | 61 | 0.010 |
Why?
| | Postoperative Period | 1 | 2003 | 329 | 0.010 |
Why?
| | Cyclosporine | 1 | 2003 | 263 | 0.010 |
Why?
| | Genes, bcl-2 | 1 | 2002 | 21 | 0.010 |
Why?
| | Utah | 1 | 2002 | 63 | 0.010 |
Why?
| | Living Donors | 1 | 2003 | 286 | 0.010 |
Why?
| | Cytokines | 1 | 2009 | 2018 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 515 | 0.010 |
Why?
| | Age Factors | 1 | 2006 | 3150 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 858 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2001 | 1491 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2000 | 428 | 0.010 |
Why?
| | Hospital Departments | 1 | 1975 | 10 | 0.010 |
Why?
|
|
Norman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|